Equities

Ribomic Inc

4591:TYO

Ribomic Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)83.00
  • Today's Change0.00 / 0.00%
  • Shares traded486.20k
  • 1 Year change-30.25%
  • Beta1.2313
Data delayed at least 20 minutes, as of Nov 22 2024 06:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in JPYIncome statement in JPYView more

Year on year Ribomic Inc had revenues fall -100.00% from 65.97m to 0.00, though the company grew net income from a loss of 1.65bn to a smaller loss of 1.02bn.
Gross margin--
Net profit margin-45,053.58%
Operating margin-51,591.46%
Return on assets-25.76%
Return on equity-26.68%
Return on investment-26.68%
More ▼

Cash flow in JPYView more

In 2024, cash reserves at Ribomic Inc fell by 725.44m. However, Cash Flow from Investing totalled 177.27m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 932.76m for operations while cash generated from financing totalled 27.65m.
Cash flow per share-25.50
Price/Cash flow per share--
Book value per share80.86
Tangible book value per share80.86
More ▼

Balance sheet in JPYView more

Ribomic Inc appears to have little financial risk as the company holds a substantial amount of cash on its books with little or no debt.
Current ratio30.90
Quick ratio30.87
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.